ArticleNature cancer2021
Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities.
Article in Nature cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Two decades of progress in gastric cancer peritoneal metastasis: a bibliometric perspective on molecular mechanisms and therapeutic innovations.Frontiers in oncology · 2025Pooled it
- Super-Enhancer Formation in Scirrhous Gastric CAFs, and the Presence of a Stromal Field in Non-Cancerous Tissues.Cancer science · 2026Article
- A 3D pooled PBMC-organoid co-culture platform for profiling immune susceptibility and PD-1 blockade response in gastric cancer.BMC medicine · 2026Article
- The "Hit-and-Run" legacy: epigenetic locking and the survival switch in H. pylori-associated gastric cancer.Cell death discovery · 2026Review
- Review
- Gastric Cancer: Pathobiology and Therapeutics.MedComm · 2026Review
- Advances in the molecular subtyping of gastric cancer.World journal of surgical oncology · 2026Review
- Divergent clonal evolution and tumor microenvironment remodeling shape gastric cancer peritoneal metastasis.Communications biology · 2026Article
- RNA mCell biology and toxicology · 2026Review
- Comprehensive genomic profiling of triple-negative breast cancer metastases identifies role of PKD1 in immunotherapy resistance.The Journal of clinical investigation · 2026Article
- Genomic landscape of paired primary and peritoneal metastatic lesions in gastric cancer highlights evolutionary dynamics and mutational drivers.Journal of advanced research · 2026Article
- Targeting super-enhancer-driven SKIL transcription by CDK7 inhibitor THZ1 to suppress gastric cancer progression.Journal of translational medicine · 2026Article
- Urinary metabolomics-based machine learning for diagnosis of early gastric neoplasia: a retrospective diagnostic case-control study.Frontiers in oncology · 2026Article
- Electroporation-Induced Gastric Cancer Models Through Epithelial-Specific Genetic Modifications.Gastro hep advances · 2026Review
- Bladder metastasis from gastric cancer presenting as acute post-renal obstruction during immunotherapy: a case report.Frontiers in oncology · 2026Article
- Pan-cancer clinicopathological and genomic characteristics of peritoneal metastasis.NPJ precision oncology · 2025Article
- A preserved TGFβ cytostatic response through DLD-mediated metabolic modulation undermines anti-TGFβ therapy in gastric cancer.Nature communications · 2025Article
- Distinct Immunosuppressive Tumor Microenvironment in Gastric Cancer With Peritoneal Metastasis.Journal of gastric cancer · 2025Article
- Proteomics analysis and immune profiling reveal regulators of PD-L1 in oesophageal squamous cell carcinoma.British journal of cancer · 2025Article
- Therapeutic strategy for scirrhous type gastric cancer.Japanese journal of clinical oncology · 2025Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal metastasis, a hallmark of incurable advanced gastric cancer (GC), presently has no curative therapy and its molecular features have not been examined extensively. Here we present a comprehensive multi-omic analysis of malignant ascitic fluid samples and their corresponding tumor cell lines from 98 patients, including whole-genome sequencing, RNA sequencing, DNA methylation and enhancer landscape. We identify a higher frequency of receptor tyrosine kinase and mitogen-activated protein kinase pathway alterations compared to primary GC; moreover, approximately half of the gene alterations are potentially treatable with targeted therapy. Our analyses also stratify ascites-disseminated GC into two distinct molecular subtypes: one displaying active super enhancers (SEs) at the ELF3, KLF5 and EHF loci, and a second subtype bearing transforming growth factor-β (TGF-β) pathway activation through SMAD3 SE activation and high expression of transcriptional enhancer factor TEF-1 (TEAD1). In the TGF-β subtype, inhibition of the TEAD pathway circumvents therapy resistance, suggesting a potential molecular-guided therapeutic strategy for this subtype of intractable GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.